Herceptin madness

References

• Romond E. H., Perez E. A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2‐positive breast cancer. N Engl J Med 2005; 353: 1673–1684
   PubMed Web of Science ®Google Scholar
• Piccart‐Gebhart M. J., Procter M., Leyland‐Jones B., et al. Trastuzumab after adjuvant chemotherapy in HER2‐positive breast cancer. N Engl J Med 2005; 353: 1659–1672
   PubMed Web of Science ®Google Scholar
• Keidan J. Sucked into the Herceptin maelstrom. Br Med J 2007; 334: 18
   PubMedGoogle Scholar
• Colditz G. A., Hankinson S. A., Hunter D. J., et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995; 332: 1589–1593
   PubMed Web of Science ®Google Scholar
• Jaga K., Dharmani C. The epidemiology of pesticide exposure and cancer: A review. Rev Environ Health 2005; 1: 15–38
   Google Scholar
• http://info.cancerresearchuk.org:8000/cancerstats/types/breast/survival/?a = 5441 (accessed 20 August 2006)
   Google Scholar
• Silvera S. A., Jain M., et al. Dietary carbohydrates and breast cancer risk: A prospective study of the roles of overall glycemic index and glycemic load. Int J Cancer 2005; 4: 653–658
   Google Scholar
• Smith I., Procter M., et al. Two‐year follow‐up of trastuzumab after adjuvant chemotherapy in HER‐2 positive breast cancer: A randomised controlled trial. Lancet 2007; 369: 29–36
   PubMed Web of Science ®Google Scholar
• Slamon D. J., Leyland‐Jones B., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 11: 783–792
   Web of Science ®Google Scholar
• Morgan G., Ward R., Barton M. The contribution of cytotoxic chemotherapy to 5‐year survival in adult malignancies. Clin Oncol (R Coll Radiol) 2004; 16((8))549–560
   PubMed Web of Science ®Google Scholar
• Mayor S. NICE approves traztuzumab for early stage breast cancer. Br Med J 2006; 332: 1409
   PubMed Web of Science ®Google Scholar
• Roche submission to NICE, Achieving clinical excellence in the adjuvant treatment of HR‐2 positive breast cancer, 7 February 2006
   Google Scholar
• Baader S. L., Bruchelt G., Trautner M. C., Boschert H., Niethammer D. Uptake and cytotoxicity of ascorbic acid and dehydroascorbic acid in neuroblastoma (SK‐N‐SH) and neuroectodermal (SK‐N‐LO) cells. Anticancer Res 1994; 14((1A))221–227
   PubMed Web of Science ®Google Scholar
• Spielholz C., Golde D. W., Houghton A. N., Nualart F., Vera J. C. Increased facilitated transport of dehydroascorbic acid without changes in sodium‐dependent ascorbate transport in human melanoma cells. Cancer Res 1997; 57((12))2529–2537
   PubMed Web of Science ®Google Scholar
• Sestili P., Brandi G., et al. Hydrogen peroxide mediates the killing of U937 tumor cells elicited by pharmacologically attainable concentrations of ascorbic acid: cell death prevention by extracellular catalase or catalase from cocultured erythrocytes or fibroblasts. J Pharmacol Exp Ther 1996; 3: 1719–1725
   Google Scholar
• Padayatty S. J., Sun H., Wang Y., Riordan H. D., Hewitt S. M., Katz A., Wesley R. A., Levine M. Vitamin C pharmacokinetics: Implications for oral and intravenous use. Ann Intern Med 2004; 140((7))533–537
   PubMed Web of Science ®Google Scholar
• Chen Q., Espey M. G., et al. Pharmacologic ascorbic acid concentrations selectively kill cancer cells: Action as a pro‐drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci USA 2005; 38: 13604–13609
   Google Scholar
• Cameron E., Pauling L. Cancer and vitamin C. Camino Books, Philadelphia 1993
   Google Scholar
• Riordan H. D., Riordan N. H., Jackson J. A., et al. Intravenous vitamin C as a chemotherapy agent: A report on clinical cases. R Health Sci J 2004; 23((2))115–118
   PubMedGoogle Scholar
• Vieth R. Vitamin D nutrition and its potential health benefits for bone, cancer and other conditions. J Nutr Environ Med 2001; 11: 275–291
   Google Scholar
• Vieth R., Chan A., Pollard A. 125I‐RIA kit cannot distinguish vitamin D deficiency as well as a more specific assay for 25‐hydroxyvitamin D. Clin Biochem 1995; 28: 175–179
   PubMed Web of Science ®Google Scholar
• Haddock L., Corcino J. Vazque z Md. 25(OH) D serum levels in the normal Puerto Rican population and in subjects with tropical sprue and parathyroid disease. Puerto Rico Health Sci J 1982; 1: 85–91
   Google Scholar
• Apperley F. L. The relation of solar radiation to cancer mortality in North America. Cancer Res 1941; 191–195
   Google Scholar
• Garland C. F., Garland F. C., et al. The role of vitamin D in cancer prevention. Am J Public Health 2006; 96: 252–261
   PubMed Web of Science ®Google Scholar
• Grant W. B. An estimate of premature cancer mortality in the US because of inadequate doses of solar ultraviolet B radiation. Cancer 2002; 94((6))1867–1875
   PubMed Web of Science ®Google Scholar
• Trump D. L., Muindi J., Fakih M., Yu W. D., Johnson C. S. Vitamin D compounds: Clinical development as cancer therapy and prevention agents. Anticancer Res 2006; 26((4A))2551–2556
   PubMed Web of Science ®Google Scholar
• Weitsman G. E., Koren R., Zuck E., Rotem C., Liberman U. A., Ravid A. Vitamin D sensitizes breast cancer cells to the action of H(2)O(2): Mitochondria as a convergence point in the death pathway. Free Radic Biol Med 2005; 39: 266–278
   PubMed Web of Science ®Google Scholar